spacer
home > ict > summer 2018 > patient privacy
PUBLICATIONS
International Clinical Trials

Patient Privacy

ICT: What is clinical trial transparency?

TrialScope: Clinical trial transparency can mean different things to different people. In its broadest sense, it is to make a wide range of information about a clinical trial available to the public. This includes registering the trial at the time that it begins enrolling participants, disclosing summary results of the trial once it completes, sharing the more detailed study report and anonymised patient data, and providing a plain-language summary of the trial results. All of these components have legal or regulatory requirements, but organisations are pressured to share more than what is legally mandated.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Wicks, Chief Strategy Officer at TrialScope, has more than 17 years of experience with performance and content management solutions, specialising in applications for life sciences such as clinical trial disclosure, structured product labelling, and submissions management. Thomas has been on the PharmaCM team since 2007. Prior to the acquisition of PharmaCM by TrialScope, he served as the General Manager of PharmaCM at Deloitte and as the Director of PharmaCM Product Management at Intrasphere Technologies. Before joining Intrasphere, Thomas worked in leadership, client-facing positions for Revelwood and Shepherd Systems, focussed on performance management solutions.

Francine Lane is the Vice President of Global Transparency at TrialScope. In this role, she is responsible for helping TrialScope customers meet and exceed current disclosure expectations globally, giving them the tools they need to meet all the requirements in this evolving industry. Francine also dedicates her time to building relationships with external stakeholders, including sponsors, investigators, regulators, and transparency and patient advocates, to help align the goals and expectations of these groups, as well as help identify more consistent ways sponsors can meet industry standards. Prior to her role as Vice President of Global Transparency, Francine served as Director of Product Management at TrialScope.
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement